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apresentação gráﬁca do conteúdo textual (veriﬁcadas no estudo analítico) podem 
inﬂuenciar negativamente nas estratégias de leitura da bula, particularmente pelos 
participantes com pouca experiência de leitura com este tipo de documento. CON-
CLUSÕES: Com base nos resultados de ambos os estudos foram elaboradas diretrizes 
e espera-se que estas possam contribuir com a melhoria na qualidade da estrutura e 
apresentação gráﬁca do conteúdo textual da bula de medicamento no Brasil.
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THE IMPACT OF FAMILY PHYSICIAN PROGRAM ON HEALTH 
INDICATORS IN IRAN (2003–2007)
Barati O
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OBJECTIVES: “ Family Physician” program has been launched since 2005 as a fun-
damental health plan in Iran. In spite of valuable information gathered through vital 
horoscope, only a few studies have been done in order to evaluate the performance 
of this program. So this research has been carried out to assess the impact of this 
program on heath indicators. METHODS: The research involved collecting data about 
11 main health indicators extracted from the ofﬁcial annual report of the deputy for 
health from 2001 to 2006 and analyzing them through t- paired test in SPSS RESULTS: 
Statistical analysis shows that the changes in 6 main indicators during these years 
including infant mortality rate, (IMR), crude birth rate, under-5 mortality rate 
(U5MR), neonatal mortality rate (NMR), maternal mortality rate (MMR), and per-
centage of deliveries attended by unskilled persons were signiﬁcant (p-value  0/05) 
and all of the above indicators have decreased during these years. Although other 5 
indicators such as crude death rate(CDR), general fertility rate, percentage of deliveries 
in hospitals, percentage of family planning coverage and still birth rate had an appro-
priate improvement during these years, their changes were not statistically signiﬁcant 
(p-value  0/05). CONCLUSIONS: Findings indicates that there is an acceptable 
improvement in many of the health indicators since starting this program. But this 
does not mean that the other factors that might have affect on these indicators should 
not be considered.
INFECTION – Clinical Outcomes Studies
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OBJECTIVES: Gender differences in cardiovascular risk (CVR) among HIV-infected 
patients have been reported, with conﬂicting results. We have previously reported data 
from the Registry and Prospective Analysis of Patients Infected with HIV and Dyslip-
idemia (RAPID II study) a higher CVR in males and higher rates of obesity, metabolic 
syndrome (MS), and lack of physical exercise in females. We now compare gender 
differences among Brazilian individuals METHODS: Adult HIV-infected patients with 
at least 6 months of HAART were enrolled in this longitudinal study that is being 
conducted in 7 countries. Metabolic proﬁle, anthropometric parameters, CD4-cell 
count, viral load (VL), types of HAART, CVR factors, and Framingham score were 
compared by gender RESULTS: A total of 1001 Brazilian patients were enrolled, 655 
(65.4%) were males. Mean (SD) age was 44 (10) years, mean time on HAART was 
48.4(36.4) months, 48% were on a protease inhibitors-based HAART, mean CD4-cell 
count was 519 (274) cells/mm3, and mean VL was 2.29 (0.9) log10 copies/ml. Males 
were found to have higher 10-year CVR (15.9 o 30.1 vs 11.0 o 29.6; P  0.0136) and 
were more likely to belong to the high-risk category (15.9% vs 10.4%; P  0.021) 
than females. No gender differences were found in the rates of hypertension, type II 
diabetes, or MS. Female patients showed higher prevalence of obesity (12.7% vs 7.2%; 
P  0.005) and physical inactivity (66.5% vs 53.6%; P  0.001) than males. In con-
trast, male patients were older (44.5 o 9.4 vs 43.0 o 10.4 years; P  0.0194), and had 
higher rates of smoking (24.4% vs 17.6%; P  0.016) and dyslipidemia (81.8% vs 
74.6%; P  0.009) than females CONCLUSIONS: Brazilian individuals sheds light 
on gender differences whose recognition may be important for appropriate interven-
tion on modiﬁable CVR factors.
PIN2
INTEGRATION OF PHARMACO-ECONOMIC OUTCOME BASED 
RESEARCH WITH LOCAL CONTEXT: A MODEL FOR RATIONAL 
HEALTH CARE DECISION-MAKING IN DEVELOPING COUNTRIES
Mathew JL
Postgraduate Institute of Medical Education and Research, Chandigarh, India
BACKGROUND: Extrapolation of research data from developed countries, without 
considering the local context can sometimes result in outcomes different from the 
research setting, emphasizing the need to integrate external research with local context. 
An example of hepatitis B vaccination in India is presented as a model. OBJECTIVES: 
To decide whether hepatitis B vaccination should be introduced in India, by integrating 
pharmaco-economic research data with the local context. METHODS: Detailed 
literature search was undertaken to identify evidence for: 1) hepatitis B disease burden 
in India; 2) efﬁcacy and safety of Hepatitis B vaccination; 3) economic implications; 
4) feasibility of universal administration; 5) local situation; and 6) expected short and 
long term outcome. Evidence was sought in the following hierarchy: systematic 
reviews, randomized trials and case control/cohort studies. RESULTS: A current sys-
tematic review1 identiﬁed Hepatitis B prevalence as 1.7%; another (Cochrane) 
review2 reported relative risk of hepatitis B following vaccination as 0.12(0.03–0.44) 
in per-protocol analysis, suggesting that prevalence could be decreased by 88% 
through universal vaccination. The cost of vaccine would be approximately 0.15US$ 
per dose and vaccination cost per child approximately 0.60US$ (1.8US$ for three 
doses) if added to DPT vaccination administered to infants at 6,10,14 weeks of age; 
thereby making the intervention highly cost-effective in terms of reduction in disease 
prevalence (short-term outcome) and hepatitis B morbidity/mortality (long-term 
outcome). However current national data3 shows that DPT vaccine coverage is only 
55.3%; further over one-third of hepatitis B infection is acquired perinatally4 and 
cannot be prevented through this vaccination schedule. Therefore, integrating local 
context with research data suggests that the expected 88% reduction in prevalence 
(from research data) would practically translate to only 37% reduction, whereby 
hepatitis B vaccination may no longer be cost-effective to reduce disease burden. 
CONCLUSIONS: It is critical to incorporate local contextual issues when pharmaco-
economic outcome data is extrapolated from external research, especially in develop-
ing countries.
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OBJECTIVES: The objective of this analysis was to apply a risk estimation model 
(REVEAL study by Chen, 2007) to predict HCC development in Brazilian CHB-
infected subjects and to estimate the level of risk according to Viral Load distribution. 
METHODS: We evaluated: gender, age, family history of HCC, prevalence of alcohol 
consumption, ALT, HBeAg and HBV DNA levels. Patients were from different regions 
of Brazil, diagnosed with CHB at the DASA in 2007. Regression coefﬁcients derived 
from the Cox models of Chen’s study were converted into risk scores (RS) and the 
predicted risks of HCC over 5 and 10 years calculated by predicted 5/10 years HCC 
risk  1-(1-P0) exp (RS-RS0); being: P0: Predicted probability of HCC within 5/10 
years for persons with the reference-level risk score RS0 and RS: Risk score of which 
HCC risk to be predicted. Costs for treatment was reported by Castelo (2007). 
RESULTS: Of the total population (564) 64.5% were males and 62.1% were HBeAg 
negative. The median HBV DNA level was 1,789 and 72,924 copies/mL for HBeAg 
negative and positive patients, respectively. Patients male, older with high HBV DNA 
levels had the greatest risk of developing HCC. The mean (SD) estimated risk for 5 
and 10 years in 1000 patients are 7.87 (6.82) and 18.30 (15.77), respectively. In 
patients older than 40 years old this risk is 27.34 (13.82) and for patients with HBV 
DNA levels higher than 10,000, the risk is 26.54 (15.75). The costs for treating these 
patients can vary from US$34,861.50 to US$50,558.70, if these patients are trans-
planted these costs can be from US$639,548.40 to US$927,519.92. CONCLUSIONS: 
This study suggests that the risk of HCC in the Brazilian HBV population is consider-
able and may signicantly impact the health care system.
INFECTION – Cost Studies
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OBJECTIVES: The distribution of Chronic hepatitis B virus (HBV) in various Brazil-
ian regions is not well understood. The public health and economic impact of Hepatitis 
B and its complications such as cirrhosis, and liver cancer in the Brazilian Uniﬁed 
Health System (SUS) will give further insights of the importance of the disease in 
Brazil. DATASUS is a public administrative database maintained by MoH and can 
contribute to the study of HBV. METHODS: HBV and its complications in the Brazil-
ian SUS was evaluated in the public database DATASUS between 2000 to 2007. Data 
were tabulated according with different Brazilian states. RESULTS: Mortality data 
indicate a peak of viral hepatitis and liver cirrhosis between 40 to 60 years old, fol-
lowed by another mortality peak due to liver cancer between 60 to 80 years old, this 
pattern is found in the states studied. The average hospitalization time for liver-related 
